Peel Hunt restated their buy rating on shares of Circassia Pharmaceuticals (LON:CIR) in a report released on Tuesday, LSE.Co.UK reports. The brokerage currently has a GBX 70 ($0.91) price target on the stock.
CIR has been the subject of a number of other reports. FinnCap began coverage on shares of Circassia Pharmaceuticals in a research note on Thursday, September 26th. They issued a corporate rating and a GBX 80 ($1.05) price objective for the company. Peel Hunt lowered their price objective on shares of Circassia Pharmaceuticals from GBX 90 ($1.18) to GBX 70 ($0.91) and set a buy rating for the company in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Circassia Pharmaceuticals presently has an average rating of Buy and an average target price of GBX 79 ($1.03).
LON:CIR opened at GBX 17.18 ($0.22) on Tuesday. Circassia Pharmaceuticals has a 1-year low of GBX 13.25 ($0.17) and a 1-year high of GBX 72.20 ($0.94). The company has a 50-day moving average of GBX 17.24 and a 200 day moving average of GBX 21.64. The firm has a market cap of $64.44 million and a PE ratio of -0.51. The company has a debt-to-equity ratio of 21.61, a current ratio of 0.40 and a quick ratio of 0.35.
In other news, insider Jonathan Emms purchased 300,000 shares of the firm’s stock in a transaction on Monday, September 30th. The stock was acquired at an average cost of GBX 17 ($0.22) per share, with a total value of £51,000 ($66,640.53).
Circassia Pharmaceuticals Company Profile
Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of respiratory diseases. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; and Tudorza for the treatment of chronic obstructive pulmonary disease (COPD).
Featured Article: What are the Different Types of Leveraged Buyouts?
Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.